Bing Yang Yang

US Patent:

6569406, May 27, 2003

Filed:

Aug 7, 2001

Appl. No.:

09/923519

Inventors:

Cynthia Stevenson - Mountain View CA
Jayne E. Hastedt - San Carlos CA
S. Russ Lehrman - Los Altos CA
David B. Bennett - San Jose CA
David Lesikar - Palo Alto CA
Bing Yang - Redwood City CA
David Gong - San Mateo CA
Kirsten Cabot - San Francisco CA

Assignee:

Nektar Therapeutics - San Carlos CA

International Classification:

A61K 900

US Classification:

424 43, 46489, 12820315, 514 2

Abstract:

The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 -helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i. e. , demonstrating superior aerosol performance).

US Patent:

6838075, Jan 4, 2005

Filed:

Mar 14, 2003

Appl. No.:

10/389628

Inventors:

Cynthia Stevenson - Mountain View CA, US
Jayne E. Hastedt - San Carlos CA, US
Russ Lehrman - Los Altos CA, US
David B. Bennett - San Jose CA, US
David Lesikar - Palo Alto CA, US
Bing Yang - Redwood City CA, US
David Gong - San Mateo CA, US
Kirsten Cabot - San Francisco CA, US

Assignee:

Nektar Therapeutics - San Carlos CA

International Classification:

A61K 912
A61K 914

US Classification:

424 43, 424 45, 424489, 514 2, 530300, 12820315

Abstract:

The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 α-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i. e. , demonstrating superior aerosol performance).

US Patent:

7223761, May 29, 2007

Filed:

Oct 1, 2004

Appl. No.:

10/956251

Inventors:

Henry T. Kruk - San Jose CA, US
Lawrence R. McGee - Pacifica CA, US
Bing Yang - Redwood City CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 31/497
A61K 31/47
C07D 215/38
C07D 215/44
C07D 215/46

US Classification:

51425204, 514311, 514312, 546153, 546159, 546160, 546161

Abstract:

Salts and polymorphs of a compound useful in the treatment of inflammatory and metabolic conditions and diseases are provided herein. In particular, the invention provides salts and polymorphs of a compound which modulates the expression and/or function of a peroxisome proliferator-activated receptor. The salts and polymorphs are useful for the treatment or prevention of conditions and disorders associated with energy homeostasis such as type II diabetes, lipid metabolism, adipocyte differentiation and inflammation.

US Patent:

7473433, Jan 6, 2009

Filed:

Dec 21, 2001

Appl. No.:

10/032239

Inventors:

Michael Weikert - Belmont CA, US
Marc S. Gordon - Sunnyvale CA, US
Sandeep Kumar - Sunnyvale CA, US
Bing Yang - Redwood City CA, US
Razaq Sarwar - Fremont CA, US

Assignee:

Nektar Therapeutics - San Carlos CA

International Classification:

A61K 9/14
A61K 9/50

US Classification:

424489, 424500, 424501, 424502

Abstract:

The present invention provides spray-dried polyene compositions for oral inhalation to the lung. The polyene antifungal compositions demonstrate superior aerosol properties, do not exhibit appreciable degradation of the polyene upon spray-drying, and are useful in the treatment and prophylaxis of both pulmonary and systemic fungal infections.

US Patent:

8003665, Aug 23, 2011

Filed:

May 24, 2007

Appl. No.:

11/807208

Inventors:

Henry T. Kruk - San Jose CA, US
Lawrence R. McGee - Pacifica CA, US
Bing Yang - Redwood City CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 31/04

US Classification:

514312

Abstract:

Salts and polymorphs of a compound useful in the treatment of inflammatory and metabolic conditions and diseases are provided herein. In particular, the invention provides salts and polymorphs of a compound which modulates the expression and/or function of a peroxisome proliferator-activated receptor. The salts and polymorphs are useful for the treatment or prevention of conditions and disorders associated with energy homeostasis such as type II diabetes, lipid metabolism, adipocyte differentiation and inflammation.

US Patent:

8299025, Oct 30, 2012

Filed:

Apr 22, 2008

Appl. No.:

12/148896

Inventors:

Thomas R. Alessi - Hayward CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US

Assignee:

Intarcia Therapeutics, Inc. - Hayward CA

International Classification:

A61K 38/26
A61P 3/10

US Classification:

514 72, 514 68, 514 69

Abstract:

A suspension formulation of an insulinotropic peptide (e. g. , glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.

US Patent:

8343140, Jan 1, 2013

Filed:

Feb 12, 2009

Appl. No.:

12/378341

Inventors:

Thomas R. Alessi - Hayward CA, US
Karling Alice Leung - Oakland CA, US
Ryan D. Mercer - Dublin CA, US
Cristina G. Negulescu - Santa Clara CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US

Assignee:

Intarcia Therapeutics, Inc. - Hayward CA

International Classification:

A61K 9/22

US Classification:

6048921

Abstract:

The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.

US Patent:

20050123509, Jun 9, 2005

Filed:

Oct 16, 2002

Appl. No.:

10/493181

Inventors:

S. Lehrman - Los Altos CA, US
Bing Yang - Redwood City CA, US
Cynthia Stevenson - Mountain View CA, US

International Classification:

A61K038/28
B29B009/00
A61K031/727
A61K038/21
A61K039/395

US Classification:

424085200, 514012000, 514056000, 424130100, 264005000, 424085400, 514003000

Abstract:

Methods are provided for preparing spray-dried, drug-containing particles comprising the steps of selecting (i) a drug and an optional excipient, wherein the combination of the drug and optional excipient has an effective pI, and (ii) an aqueous solution having a pH that is different from the effective pI; (b) combining the solution and the drug and optional excipient, wherein an absolute net charge is associated with the drug and optional excipient as a result of an absolute difference between the pH and effective pI; and (c) spray drying the solution to form the spray-dried, drug-containing particles. Particles and compositions comprising the prepared particles as well as methods of use are also provided.